Featured
Read our handpicked blogs, curated for you.
|
For Indian pharma, HCP engagement is no longer about reach; it’s about relevance and measurable impact. Boards want to…
|
Pharma marketing in India is at a turning point. Budgets have expanded, channels have multiplied, and compliance…
|
If you’re serious about HCP Engagement Tier 2 Cities, stop chasing metro playbooks. Tier 2 doctors don’t sit in front…
Recent releases
|
UCPMP 2024 Guide to Pharma Marketing Compliance and Faster MLR
Introduction: Why UCPMP 2024 Is a Turning PointUCPMP 2024 is not another guideline update. It is a reset for how pharma marketing works in India. For years, many companies have navigated compliance…
|
AI in Pharma and Healthcare: AI use cases that actually drive pharma scripts
The conversation around AI in Pharma and Healthcare has been dominated by hype. Predictions about robots replacing reps, algorithms discovering blockbuster drugs overnight, and chatbots taking over…
|
MLR in healthcare: How to cut approval time by half without risk
Every healthcare marketer in India knows the pain of the MLR cycle. Content is drafted, sent for review, marked up, revised, sent back again, and weeks later, the campaign is still waiting for…
|
How to finally prove ROI in pharma marketing
Every pharma CMO in India has faced the same boardroom moment: a director asks, “We’ve spent ₹50 crores on marketing this year. What’s the ROI?” The room falls silent. Spreadsheets shuffle. Activity…
